- Home
- PENG vs MLTX Comparison
PENG vs MLTX Comparison
Compare PENG & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | MLTX |
|---|---|---|
| Founded | 1988 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 972.7M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | PENG | MLTX |
|---|---|---|
| Price | $20.37 | $13.92 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $27.50 | ★ $36.33 |
| AVG Volume (30 Days) | 798.6K | ★ 1.7M |
| Earning Date | 01-06-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.28 | N/A |
| Revenue | ★ $1,368,794,000.00 | N/A |
| Revenue This Year | $8.56 | N/A |
| Revenue Next Year | $15.95 | N/A |
| P/E Ratio | $72.46 | ★ N/A |
| Revenue Growth | ★ 16.91 | N/A |
| 52 Week Low | $14.20 | $5.95 |
| 52 Week High | $29.80 | $62.75 |
Technical Indicators
Market Signals| Indicator | PENG | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 49.63 |
| Support Level | $19.65 | $13.32 |
| Resistance Level | $20.27 | $14.12 |
| Average True Range (ATR) | 0.64 | 0.77 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 26.71 | 32.45 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.